Over the last decades, heart failure with preserved ejection fraction (HFpEF) has received less attention by the medical and scientific communities, which led to the emergence of a number of misconceptions concerning its characteristics, diagnostic and therapeutic approach.
Introduction
Heart failure (HF) represents a major and growing public health problem, affecting 2% -3% of adults in developed countries 1 
.
Patients with heart failure are classically divided into two groups: those with HF with preserved ejection fraction (HFpEF), also called diastolic HF (DHF) and those with HF and reduced ejection fraction (HFrEF), better known as systolic HF (SHF) 1 .
In recent decades, HFpEF has received much less attention from medical and scientific communities, a situation that is finally starting to change. Such lack of attention resulted in the gradual emergence, within the medical community, of a series of misconceptions and dogmas concerning the epidemiology, diagnosis, pathophysiology and treatment of HFpEF.
With this review, we intend to explore and tackle the major misconceptions associated with HFpEF. We will discuss the latest evidence concerning HFpEF, providing a new view on this complex syndrome, in order to improve its clinical and therapeutic approach.
Frequent misconceptions in heart failure with preserved ejection fraction Misconception 1: HFpEF is a benign condition Until recently, HFpEF had been considered an essentially "benign" disease associated with a better prognosis. Epidemiological studies have shown that the prognosis for these patients is as bad as those who have systolic HF (SHF) 2, 3 . Patients with HFpEF have mortality rates of 29% after one year (versus 32% in patients with systolic HF), and 65% after five years (versus 68%) 3 .
The morbidity of HFpEF is also very high, requiring frequent admissions and a significant consumption of resources 4, 5 . Once admitted due to HF, these patients have a high rate of readmission of 50% after one year 5 .
Equally worrying is the evidence showing that the survival of patients with HFpEF has not been improving in recent decades, unlike what has been observed in patients with systolic HF 6 . Such observation is probably related to the fact that the management and treatment of these patients are not producing the desired effects, probably due to various misconceptions concerning HFpEF.
Misconception 2: diastolic HF is an uncommon syndrome
A second misconception in HFpEF is to think that this is a clinical condition that is less common than the SHF. This is quite the opposite! We know today that HFpEF is responsible for about 50% of all patients admitted with HF, a proportion that increases with age 2, 4, [6] [7] [8] . Moreover, in the last two decades the proportion of patients with HFpEF increased from 38% to 54% out of cases of HF 6 , a proportion that will continue to rise due to the progressive aging of population and expected increase in the prevalence of hypertension, obesity and diabetes.
Misconception 3: diastolic HF and systolic HF are the same condition
The classical separation of HF in HFpEF is questioned by several authors who argue that these relate to the same condition, albeit with different phenotypes 9, 10 . However, there are many demographic, epidemiological, histological, molecular and structural arguments, as well as some relating to ventricular function and even therapeutic effectiveness, which seem to clearly indicate that these two conditions are quite different (Table 1) 6, 11 .
Regarding the characteristics of the population, patients with HFpEF are older, often female, and have a high prevalence of hypertension, diabetes and obesity, as well as various comorbidities such as atrial fibrillation, renal failure and anemia [2] [3] [4] 7, 12, 13 (Table 1) .
The hearts of patients with systolic HF and HFpEF also have significant differences in terms of structure and ventricular function ( Table 1) . The hearts of patients with SHF present an eccentric ventricular modeling with increased diastolic volumes and the main anomaly occurs in LV systolic properties 14 ( Figure 1 ). By contrast, patients with HFpEF present as concentric remodeling, the volumes are normal or even reduced, and the main change occurs in the diastolic properties, with delayed relaxation and/or increased ventricular stiffness [14] [15] [16] ( Figure 1 and Table 1 ).
Other recently published studies have also shown differences at histological and molecular level. For example, analysis of endomyocardial biopsies revealed that cardiomyocytes of patients with HFpEF are structurally different, with larger diameters, greater stiffness and increased density of myofilaments, compared to patients with ICS 17 . Significant differences were also discovered at the molecular level. Titin is a molecule found inside the sarcomere which, given its elastic properties, is the main determinant of the stiffness of cardiomyocytes. It was found that in patients with HFpEF there is a change in the expression of the isoforms of this molecule -with increased expression of the stiffer isoform -or its degree of phosphorylation, which contributes to the increase in ventricular stiffness observed in these patients 17, 18 . Patients with HFpEF and systolic HF also have significant differences in fibrosis and extracellular collagen matrix, due to distinct patterns of extracellular matrix metalloproteinases (MMP) and tissue inhibitors of such metalloproteinases (TIMP) activation. While in HFpEF there is a decreased degradation of extracellular matrix (resulting in increased ventricular stiffness), in dilated cardiomyopathy there is an increased matrix degradation 19, 20 . In the HFpEF, diastolic dysfunction ca occur due to changes in the passive properties of the ventricle -particularly increased ventricular stiffness -or due to alterations in myocardial relaxation. The delay in myocardial realaxation seen in patients with HFpEF is caused by changes in calcium kinetics, especially by reduced activity of SERCA 2 , the main protein responsible for the reuptake of calcium back into the sarcoplasmic reticulum 21 .
Finally, strong arguments related to the response to pharmacological therapy justify the separation of these two conditions. Few clinical trials performed to date on HFpEF reveal that these patients do not respond as well to therapy commonly used in systolic HF, suggesting that different pathophysiological mechanisms operate in these two conditions. These differences mean that the therapeutic approach to HFpEF must be different from that used in systolic HF, as prescribed in the guidelines for heart failure 1, 22 . Diastolic dysfunction plays a central role in the pathophysiology of this condition, since most patients present delayed myocardial relaxation and/or increased ventricular stiffness 23 . This is why HFpEF is often referred to as diastolic HF. More recently, after the discovery of other mechanisms that appear to contribute to the pathophysiology of this condition, the expression diastolic HF was replaced by a more general term: HFpEF 1, 24 .
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On the other hand, we know that LV diastolic dysfunction, by itself, does not seem to be enough to cause the clinical picture of heart failure. There is an important group of patients who have diastolic dysfunction, although they remain asymptomatic and without HF 25 . Moreover, the prevalence of diastolic dysfunction in the general population (present in up to 25% of the population 26 ) is much higher than the prevalence of HF. However, it remains to be explained why some patients with diastolic dysfunction have HFpEF, while others remain asymptomatic.
Beyond diastolic dysfunction: contribution of other pathophysiological mechanisms
Several studies have recently demonstrated that the pathophysiology of HFpEF involves other mechanisms, including "cardiac" and "extracardiac" factors ( Figure 2 ) 27, 28 .
The explanation for the symptomatic difference among patients with asymptomatic diastolic dysfunction and HFpEF may be due to the simultaneous existence of these additional pathophysiological abnormalities only in patients with HFpEF.
Among "extracardiac" abnormalities found in HFpEF, particular emphasis has been placed on the abnormalities found in the arterial vessels, including increased arterial stiffness, changes in ventricular-arterial coupling 29, 30 , endothelial dysfunction and reduced vasodilator reserve 31 .
There are other extracardiac factors potentially involved in HFpEF. It was found that in these patients, increased ventricular filling pressure is also due to an increased effective circulating volume due to increased sodium and water retention in the kidneys 32 . It should be stressed that in HFpEF, due to the simultaneous increase of ventricular and arterial stiffness, patients are very sensitive to small changes in the "central" volume 16 .
Recently, new "cardiac" factors have been found to contribute to HFpEF pathophysiology, such as chronotropic incompetence 31 and changes in ventricular stretching, radial deformation and twisting, evaluated by speckle tracking analysis 33 .
Finally, HFpEF patophysiology is usually accessed at rest. However, several studies have shown that additional alterations occur during exercise in HFpEF patients 31, [34] [35] [36] .
Is systolic function completely normal in HFpEF?
By definition, HFpEF patients have a normal ejection fraction. Nevertheless, because ejection fraction is an imprecise parameter for the evaluation of minor alterations in systolic function, it has been demonstrated that patients with HFpEF also have changes in systolic function assessed by Tissue 37, 38 . Also, a recent study has shown that in HFpEF patients important alterations in systolic function also occur especially in response to exercise . According to this document, three prerequisites should be fulfilled simultaneously to diagnose HFpEF: 1) symptoms and signs of HF; 2) EF> 50% in a non-dilated LV (defined as LV with a end diastolic volume < 97 ml/m 2 ); 3) evidence of high LV filling pressures.
-Left ventricular loops and pressure-volume (P-V) ratios in systolic and diastolic dysfunction. Panels A, B and C show dashed loops and P-V ratios of a normal heart. Line 1 corresponds to the end diastolic pressure-volume relation, line 2 to P-V loop and line 3 to the end systolic pressure volume relation. In the presence of systolic dysfunction (panel B, full line) there is a decreased in ejection fraction (translated by the smaller width of the P-V loop) and a reduced myocardial contractility, expressed by the lower slope of the end systolic pressure volume relation (arrow). As opposed to that, in diastolic dysfunction (Panel C), the end diastolic pressure-volume relation is shifted upwards and to the left (gray line). That makes a certain amount of ventricular filling to be only achieved at the expense of much higher filling pressures than those observed for the same volume in a normal individual (see points A and B of panel C). (Adapted from Rev
The demonstration of high LV filling pressures can be made by invasive hemodynamic evaluation (which is the goldstandard method, but is difficult to apply in clinical practice) or by combining several echocardiographic parameters together with natriuretic peptides quantification. By echocardiography several diastolic parameters can be obtained that allow LV filling pressures estimation 39 . The most widely used parameter, and also the easiest to analyse, is the E/e' ratio, which is obtained from the ratio between the peak transmitral flow velocity (E wave) and the mitral annulus velocity, determined from Tissue Doppler analysis (the e' wave) (Fig. 3) . When the E/e' ratio at the level of the septal wall is > 15, LV filling pressures are certainly increased, whereas a E/e' ratio < 8 represents normal LV filling pressures 24 . However when the E/e' ratio is between 8 and 15, it is necessary to combine this value with other diastolic function echocardiographic parameters, as discussed later.
The new diagnostic algorithm of HFpEF, despite a few limitations 28 allowed standardizing the diagnosis of HFpEF.
Misconception 6: diastolic function evaluation by echocardiography is inaccurate and has no influence on clinical management strategies
The assessment of LV diastolic function should be an integral part of routine echocardiographic evaluation 40 , especially in patients with dyspnoea and/or heart failure, due to its diagnostic 24 and prognostic significance 41 .
Initially, the diastolic function by echocardiography was mainly assessed through pulsed Doppler analysis of transmitral flow pattern. When this parameter is used alone, it is little specific, and has several limitations. This fact has led to the emergence of the (misconceived) idea that the echocardiographic assessment of diastolic function is little specific and little useful in clinical practice. Today, there are several echocardiographic parameters in the assessment of diastolic function, whose applications, advantages and limitations have been the target of a consensus document of the European and American societies of Echocardiography 39 , which will be briefly addressed in this study (Table 2) .
Pulsed Doppler transmitral inflow pattern
The analysis of transmitral flow by pulsed Doppler is easy to obtain in almost all patients (Fig. 4, A) . By analyzing transmitral filling pattern, it is possible to define four degrees of diastolic dysfunction (Fig. 3) .
Nevertheless, this parameter has several limitations ( Table 2) 39 because when used alone, it is not possible to distinguish a normal pattern from a pseudonormal, which indicates a grade II diastolic dysfunction (Figure 3) . Despite its limitations, when combined with other diastolic dysfunction parameters, the evaluation of the E/A ratio can be useful in clinical practice to support the diagnosis of HFpEF 24 . and give prognostic information, when a restrictive pattern is present 41 . 
Isovolumic relaxation time (IVRT)
This parameter, which assesses primarily the ventricular relaxation, measures the time interval between aortic valve closure and mitral valve opening (Fig. 5, panel C) . The normal value of IVRT is 70-90 msec, a value that increases with delayed relaxation, but shortens when filling pressures are markedly increased 39 .
Mitral flow propagation velocity (Vp)
The mitral flow propagation velocity (Vp) is evaluated according to Figure 5 , panel A. When ventricular relaxation is delayed, the Vp slope is reduced.
Pulmonary vein flow velocity assessment
The pulmonary vein flow assessment can provide several measurements for diastolic function evaluation. However, the most reliable parameter is the Ar pulm -Ad mitral, which is the time difference between the duration of reversed pulmonary vein flow during atrial systole (Ar pulm) and the duration of the mitral A wave flow ( Figure 5, B) ; when the Ar pulm -Ad mitral difference is > 30 msec, LV filling pressures are increased 24 .
Tissue Doppler assessment at the mitral annulus and E/e' ratio
The most widely used echocardiographic parameter for diastolic function evaluation is the E/e'(see figure 4) 24, 40 , which is the ratio of the E wave velocity from transmitral flow divided by the e' wave velocity obtained by Doppler tissue at the mitral annulus level. By applying the pulsed tissue Doppler at the septal or lateral side of the mitral annulus, it is possible to evaluate the velocity of the mitral annulus displacement and calculate the velocity of the systolic wave (S wave), of the early diastolic wave (E', e' or Ea) and of the late diastolic wave (A', a' or Am).
Several studies have shown that E/e' ratio correlates closely with LV filling pressures, independently from ejection fraction values. When E/e' ratio at the septal side of the mitral annulus is > 15, LV filling pressures are increased, whereas an E/e' value < 8 indicates normal filling pressures. However, when the e' is evaluated at the lateral side of the mitral annulus, and not at the septal wall, a cut-off of E/e' > 12 (instead of 15) should be used, because displacement velocities are greater at the lateral side 42 .
Left atrial volume
Increased left atrial volume (LA) (Fig. 5, D) is a morphological marker of chronically increased diastolic filling pressures 43 and is an important mortality predictor 44 . LA volume can also be increased in atrial fibrillation or significant mitral valve disease, therefore it is important to combine this parameter with the patient's clinical condition and with other echocardiographic markers of diastolic dysfunction 39 .
Myocardial strain analysis
Myocardial strain can now be evaluated by echocardiography using speckle tracking, which can provide essential information regarding diastolic function 39 , and may be a more reliable marker of diastolic dysfunction than the E/e' ratio 45 . Adapted from [43] . 
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D. Restrictive pattern (DD degrees III and IV) A. Normal
Figure 3 -Evaluation of different degrees of diastolic dysfunction using data obtained from the transmitral flow pattern (top) and analysis of tissue Doppler at the mitral annulus level (bottom). Legend: DD -diastolic dysfunction; DDT -diastolic deceleration time; E -transmitral flow velocity during early ventricular filling; A -transmitral flow velocity during atrial contraction; e'-Tissue Doppler velocity at the mitral annulus level during early ventricular filling.
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Figure 4 -E/e' ratio evaluation. The left panel shows transmitral inflow Doppler pattern, with the E wave velocity (E), the A wave velocity (A), the E wave deceleration time (DT) and the duration of the A wave (Ad mitral). The right panel illustrates the e' velocity assessment, evaluated by tissue Doppler at the lateral wall of the mitral annulus (E' lat).
Diastolic stress test
A great number of patients with diastolic dysfunction only develop symptoms during exercise. Therefore, it is important to evaluate LV filling pressures in response to exercise, by conducting a diastolic stress test.
This test can evaluate the E/e' ratio variation in response to exercise. While in individuals with normal relaxation, both E and e' velocities increase proportionally (keeping a normal E/e' ratio), in patients with diastolic dysfunction there is a progressive increase of the E/e' ratio with exercise 46 .
In conclusion, although some limitations still exist 47 , diastolic function can be reliably assessed by echocardiography, using an integrated step-by-step approach, starting with E/e' ratio evaluation. Moreover, diastolic dysfunction evaluation provides essential information for diagnosis, prognosis and management of patients with HF, particularly those with HFpEF Secondly, the few clinical trials conducted in HFpEF patients, only evaluated the effectiveness of renin-angiotensin system inhibitors. In all such studies the results were disappointing, since there was no survival benefit by using such agents. Hence, the use of other therapeutic agents in HFpEF can only be recommended theoretically or based on data obtained from observational studies.
Finally, in recent decades, the prognosis of HFpEF has remained unchanged over time, contrasting with the survival benefit observed in SHF patients 6 . This observation also demonstrates that HFpEF management strategies are still not appropriate.
Use of the renin-angiotensin system modulators
Contrary to systolic HF, in HFpEF blocking the reninangiotensin system is less useful in terms of clinical events Fontes-Carvalho & Leite-Moreira HFpEF: fighting misconceptions for a new approach reduction or survival benefit, as demonstrated using perindopril (PEP-CHF trial) 48 , irbesartan (I-PRESERVE) 49 or candesartan (CHARM-Preserved) 50 .
Role of beta blockers in HFpEF
In theory, beta blockers (BB) have various potential benefits in HFpEF treatment: i) by reducing the heart rate they increase the duration of diastole and hence ventricular filling time; ii) they decrease myocardial oxygen requirements; iii) they lower blood pressure; and iv) they may induce regression of LVH. On the other hand, these beneficial effects may be partially mitigated since BB delay ventricular relaxation and reduce contractility 16 .
Although there are no clinical trials assessing BB efficacy in HFpEF, it is expected that these agents can be potentially beneficial, especially those with a vasodilator effect (e.g. carvedilol and nebivolol), because they can also reduce arterial stiffness.
Data from observational studies indicate that beta-blockers in HFPEF may reduce mortality 51 . Recently, a subanalysis derived from the SENIORS trial showed that in the subgroup of patients with EF > 35%, the benefits of this BB were similar, which suggests that the effectiveness of BB is not depend on ejection fraction 52 . With so many uncertainties, there is an urging need for a clinical trial to test the use of BB in HFpEF.
Aldosterone antagonists in HFpEF
The use of antagonists aldosterone in HFpEF can be beneficial, at least from a theoretical standpoint. Aldosterone acts both on the myocardium and vessels, promoting myocyte hypertrophy, fibrosis and collagen deposition, all of which may contribute to increased myocardial and arterial stiffness, contributing HFpEF progression 53 . A small clinical trial demonstrated that spironolactone improved echocardiographic parameters of diastolic dysfunction 54 . A randomized clinical trial -the TOPCAT study -is currently in progress aimed at assessing the role of aldosterone antagonists in HFPEF patients.
Other therapeutic strategies
Given so many uncertainties, only some general principles are recommended for HFpEF treatment 1 : i) aggressive blood pressure control, to prevent the onset of HFpEF, to reduce the number of HF hospitalizations, to induce left ventricular hypertrophy regression and to improve ventricular-arterial coupling; ii) reduction of ventricular filling pressures, by restricting salt intake and administration of diuretics, which is particularly important since HFpEF patients are highly sensitive to changes in central volume and pre-load; iii) maintaining sinus rhythm, to preserve atrial contraction; iv) heart rate control, preventing tachycardia, which shortens diastole duration; and v) treatment of underlying comorbidities, using an integrated and multidisciplinary approach.
Potential new therapeutic targets in HFpEF
The future treatment for HFpEF is dependent on a better understanding of its pathophysiology and on multiple interventions on the various underlying physiopathological mechanisms. Due to the heterogeneous mechanisms that cause HFpEF, its treatment will always be multifactorial and individualized to each patient.
Assuming that changes in relaxation and increased stiffness are the main pathophysiological alterations in HFpEF, it is necessary to develop new therapeutic strategies that specifically target these alterations. Alagebrium, or ALT-177, is a new drug that breaks the crosslinks that form between advanced glycosylation endproducts, thereby improving diastolic function (by reducing ventricular stiffness), vascular function (by improving arterial distensibility), and ventriculararterial coupling. Small clinical trials have shown promising results in HFpEF 55 .
Given the importance of fibrosis in increasing ventricular stiffness, several studies are analyzing (with promising results) the antifibrotic effects of several growth factors, cytokines and signaling molecules 56 .
In recent years, our research group has also contributed to clarifying the determinants of left ventricular passive properties, demonstrating that ventricular stiffness is not just a passive property, but that it can be actively modulated (and reduced) using neuro-hormonal manipulation (e.g. reninangiotensin system and endothelin, among others), opening new therapeutic targets for ventricular stiffness reduction [57] [58] [59] [60] .
In HFpEF, ventricular relaxation should also be improved. As previously mentioned, relaxation is dependent on the uptake of calcium back into the sarcoplasmic reticulum by the action of SERCA 2A , which in turn is regulated by phospholamban 61 . Animal studies have shown that genetic transfer of SERCA 2A or modified phospholamban improves ventricular diastolic function 62, 63 .
Given the beneficial effects of nitric oxide (NO) on endothelial, vascular and myocardial functions, type 5 phosphodiesterase inhibitors (e.g. sildenafil) may have a role in HF treatment, including in HFpEF 64 . A clinical trial is currently in progress to assess this possibility.
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